Paul Donovan Quotes (19 Quotes)

The U.K economy is in a stronger position than many European economies, and perhaps now is the time to pause for a bit,

We continue to expect to be in a position to sign a definitive agreement in the first two weeks of January.

It was a very good quarter. We beat Wall Street consensus estimates for revenue, and we believe we met them for earnings.

We're pleased to close this chapter, and put this matter behind us. We can now direct our full attention to developing our life-saving products and technologies.

It's clear we have not done enough to resolve the issues raised by the FDA, and we recognize fully that the responsibility to do so lies with us.

We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant. I don't think we're going to have anything more to say right now.

We factored in the possibility of something like this happening. This news is manageable and does not alter our fundamental belief in Guidant's long-term potential, which is significant and very much intact.

Tax revenues are going to be lower. Fewer people will have jobs, fewer people will pay income tax, more people get unemployment benefits, so government spending goes up.

We believe our 72 proposal is better for Guidant, its shareholders and its employees than Johnson Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time.

That's important because the actual proper economic indicators are getting a bit behind the times in picking up the changes that are taking places,

The main focus this week is what the beige book is saying about the consumer sector in the U.S. because the consumer is absolutely crucial to the performance of the US economy over the course of this year - and that of course means the performance of the global economy.

We've reviewed the intellectual property issues and are comfortable proceeding with the transaction. We don't expect this issue to impact the transaction.

We continue to believe our 72 (per share) proposal is better for Guidant, its shareholders and its employees than Johnson Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant.

The intervention at 115 was pretty ineffective and they don't want to waste money again. The Bank of Japan would not be happy about defending 110 yen.

We believe this issue has no bearing on our proposed acquisition of Guidant. Unfortunately, threats of legal action are commonplace in our industry.

The issues that we addressed in our commitments were not material ones. At the request of the commission we made a number of commitments in order to resolve potential antitrust issues, as did Abbott.

If successful, we would combine the resources of two of the leading innovators in cardiovascular medicine and would expand our footprint into cardiac rhythm management. The Guidant acquisition is a natural outgrowth of our strategy to further diversify our business and accelerate growth.

What's happening is that consumers are worried about losing their jobs, and if consumers worry about losing their jobs, they spend less money -- so the economy slows down, so they lose their jobs -- it's a vicious circle.

We are seeing a belief that the Japanese economy is recovering. The Japanese are going to keep their money at home and overseas investors are going to put more to work in Japan.